BPC-157 + KPV + TB-500 Stack Guide
The Inflammation & Recovery Protocol — a comprehensive 3-peptide stack combining gut repair, molecular anti-inflammation, and systemic tissue healing for chronic inflammatory conditions and autoimmune support.
In This Guide
Verified sources for BPC-157 + KPV + TB-500
These vendors are vetted by PeptideWiki for purity testing and COA transparency.
Stack Overview
The BPC-157 + KPV + TB-500 stack is the most comprehensive anti-inflammation and recovery peptide combination available. It pairs BPC-157's localized tissue repair and gut mucosal healing with KPV's potent molecular anti-inflammation (NF-κB inhibition) and TB-500's systemic cell migration and tissue remodeling — addressing inflammation from molecular, local, and systemic levels simultaneously.
Key Characteristics:
- 3-peptide stack — BPC-157 (Body Protection Compound-157) + KPV (alpha-MSH fragment) + TB-500 (Thymosin Beta-4 fragment)
- Primary goal — systemic inflammation reduction, gut healing, tissue repair, autoimmune support, and chronic inflammatory condition management
- Triple-mechanism synergy — molecular anti-inflammation (KPV) + localized tissue repair (BPC-157) + systemic healing and cell migration (TB-500)
- Experience level — intermediate; recommended for users familiar with at least one of these peptides individually before combining all three
- Typical cycle — 6–8 weeks, extendable to 12 weeks for chronic inflammatory conditions
- Administration — BPC-157 and KPV can be taken orally (gut focus) or SubQ (systemic); TB-500 subcutaneous injection only
Use our Peptide Dosage to calculate exact doses for all three peptides based on your vial sizes and reconstitution volumes.
Why This Stack Works
This stack is effective because it attacks inflammation and tissue damage from three fundamentally different angles. Rather than relying on a single mechanism, the combination provides molecular-level, localized, and systemic coverage for comprehensive inflammatory management.
KPV: The Molecular Anti-Inflammatory
- NF-κB inhibition: directly suppresses NF-κB signaling, the master transcription factor that drives inflammatory cytokine production (TNF-α, IL-6, IL-1β)
- Alpha-MSH fragment: a tripeptide (Lys-Pro-Val) derived from the C-terminal of alpha-melanocyte-stimulating hormone, retaining its anti-inflammatory properties without melanogenic effects
- Antimicrobial activity: demonstrates direct antimicrobial properties against common gut pathogens, supporting gut microbiome balance
- Mucosal protection: reduces inflammatory infiltration in intestinal mucosa, with demonstrated benefit in colitis models
BPC-157: The Local Repair Agent
- Angiogenesis: upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation to deliver nutrients and oxygen to damaged tissue
- Gut mucosal healing: protects and repairs gastrointestinal mucosa, with demonstrated benefit in ulcer, fistula, and inflammatory bowel models
- Growth factor expression: increases EGF, FGF, and other factors that stimulate cell proliferation and tissue remodeling
- Nitric oxide modulation: interacts with the NO system to regulate blood flow, inflammation, and repair signaling
TB-500: The Systemic Healer
- Actin regulation: sequesters G-actin to promote cell migration, allowing repair cells to reach damaged tissue throughout the body
- Systemic anti-inflammation: reduces inflammation throughout the body, creating a favorable healing environment beyond any single injury site
- Tissue remodeling: promotes tissue remodeling and reduces scar tissue formation, improving functional recovery
- Blood cell production: stimulates new blood cell formation and improves endothelial cell function
The Triple Synergy
KPV suppresses the inflammatory cascade at its molecular root (NF-κB), reducing the production of inflammatory cytokines that perpetuate tissue damage. BPC-157 then creates a favorable local healing environment with new blood vessels, growth factors, and mucosal protection. TB-500 complements both by driving systemic cell migration and tissue remodeling. The result: inflammation is addressed at the source (KPV), damaged tissue is actively repaired (BPC-157), and healing cells are mobilized throughout the body (TB-500).
Individual Peptide Breakdown
Each peptide in this stack has a dedicated dosage guide with complete individual protocols. Here is a summary of each peptide's role in this stack.
BPC-157 (Body Protection Compound-157)
- Type: Synthetic pentadecapeptide (15 amino acids)
- Origin: Derived from human gastric juice proteins
- Role in stack: Localized tissue repair, gut mucosal healing, angiogenesis
- Route: SubQ (near injury) or oral (gut focus)
- Frequency: Once or twice daily
KPV (Alpha-MSH Fragment)
- Type: Tripeptide (Lys-Pro-Val, 3 amino acids)
- Origin: C-terminal fragment of alpha-melanocyte-stimulating hormone
- Role in stack: NF-κB inhibition, molecular anti-inflammation, antimicrobial
- Route: SubQ or oral (gut focus)
- Frequency: Once daily
TB-500 (Thymosin Beta-4 Fragment)
- Type: Synthetic peptide fragment of Thymosin Beta-4 (43 amino acids)
- Origin: Based on naturally occurring thymic peptide involved in cell migration
- Role in stack: Systemic anti-inflammation, cell migration, tissue remodeling
- Route: Subcutaneous injection
- Frequency: Twice weekly (loading), once weekly (maintenance)
Dosing Protocol
This stack uses different dosing frequencies for each peptide. BPC-157 and KPV are dosed daily while TB-500 follows a loading/maintenance schedule with less frequent injections.
Standard Protocol (Systemic Focus)
| Compound | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| BPC-157 | 250–500 mcg | 1–2x daily | SubQ | Consistent daily dosing throughout the entire cycle |
| KPV | 200–500 mcg | Once daily | SubQ | Consistent daily dosing; start at 200 mcg and titrate up |
| TB-500 | 2–2.5 mg | Twice weekly (loading) | SubQ | Loading phase: weeks 1–4 to build systemic levels |
| TB-500 | 2–2.5 mg | Once weekly (maintenance) | SubQ | Maintenance phase: weeks 5–8 after loading |
Gut-Focused Protocol (Oral BPC-157 + KPV)
| Compound | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| BPC-157 | 500–750 mcg | Once daily | Oral (empty stomach) | Direct GI mucosal contact; take 30 min before food |
| KPV | 200–500 mcg | Once daily | Oral (empty stomach) | Take with BPC-157 for combined gut action |
| TB-500 | 2–2.5 mg | Twice weekly (loading) | SubQ | Systemic anti-inflammatory support; 4-week loading then weekly |
Calculate Your Doses
All three peptides are supplied as lyophilized powder and need reconstitution with bacteriostatic water (for injectable use). The dose you draw depends on the concentration after reconstitution.
BPC-157 — 5 mg Vial
- Vial size: 5 mg (5,000 mcg)
- Bacteriostatic water: 2 mL
- Concentration: 5,000 ÷ 2 = 2,500 mcg/mL
- 250 mcg dose = 0.1 mL = 10 units on insulin syringe
- 500 mcg dose = 0.2 mL = 20 units on insulin syringe
- Doses per vial: 10–20 doses (depending on 500 or 250 mcg)
KPV — 5 mg Vial
- Vial size: 5 mg (5,000 mcg)
- Bacteriostatic water: 2 mL
- Concentration: 5,000 ÷ 2 = 2,500 mcg/mL
- 500 mcg dose = 0.2 mL = 20 units on insulin syringe
- Doses per vial: 10 doses (at 500 mcg)
TB-500 — 5 mg Vial
- Vial size: 5 mg (5,000 mcg)
- Bacteriostatic water: 1 mL
- Concentration: 5,000 ÷ 1 = 5,000 mcg/mL
- 2.5 mg dose = 0.5 mL = 50 units on insulin syringe
- Doses per vial: 2 doses
Skip the Math — Use Our
Enter your vial size, water volume, and desired dose for each peptide — get instant calculations with zero manual math.
Reconstitution Guide
All three peptides follow the same reconstitution process. Reconstitute each vial separately with bacteriostatic water. If using oral BPC-157 or KPV capsules, reconstitution is not needed for those peptides.
| Peptide | Vial Size | Bac Water | Concentration | Standard Dose Draw |
|---|---|---|---|---|
| BPC-157 | 5 mg | 2 mL | 2,500 mcg/mL | 10 units (0.1 mL) for 250 mcg |
| KPV | 5 mg | 2 mL | 2,500 mcg/mL | 20 units (0.2 mL) for 500 mcg |
| TB-500 | 5 mg | 1 mL | 5,000 mcg/mL | 50 units (0.5 mL) for 2.5 mg |
Wash Hands & Prepare Workspace
Wash hands thoroughly. Lay out supplies: peptide vials, bacteriostatic water, insulin syringes, and alcohol swabs on a clean surface.
Swab All Vial Stoppers
Remove plastic caps and swab the rubber stoppers of each peptide vial and the bacteriostatic water vial with alcohol pads. Let air-dry for 10–15 seconds.
Add Water to Each Peptide Vial
Draw the appropriate volume of bacteriostatic water for each vial. Insert needle and direct the stream down the inside glass wall — never squirt directly onto the powder. Release slowly. Reconstitute each vial separately.
Dissolve Gently
Let each vial sit for 1–2 minutes, then gently swirl or roll between palms until fully dissolved. Solution should be clear and colorless. Never shake.
Label & Refrigerate
Write the reconstitution date and concentration on each vial. Store all vials refrigerated at 2–8°C. Use within 28–30 days.
For a detailed visual walkthrough, see our Reconstitution Guide.
Timing & Daily Schedule
BPC-157 and KPV are dosed daily, while TB-500 follows a different schedule. Here is how a typical week looks during the loading phase (weeks 1–4):
| Day | BPC-157 | KPV | TB-500 |
|---|---|---|---|
| Monday | 250 mcg AM + 250 mcg PM | 500 mcg AM | 2.5 mg |
| Tuesday | 250 mcg AM + 250 mcg PM | 500 mcg AM | — |
| Wednesday | 250 mcg AM + 250 mcg PM | 500 mcg AM | — |
| Thursday | 250 mcg AM + 250 mcg PM | 500 mcg AM | 2.5 mg |
| Friday | 250 mcg AM + 250 mcg PM | 500 mcg AM | — |
| Saturday | 250 mcg AM + 250 mcg PM | 500 mcg AM | — |
| Sunday | 250 mcg AM + 250 mcg PM | 500 mcg AM | — |
Timing Notes
- BPC-157: Split doses 8–12 hours apart (e.g., 8 AM and 8 PM). For oral dosing, take on an empty stomach 30 minutes before food.
- KPV: Take once daily in the morning. For oral dosing, take with oral BPC-157 on an empty stomach. For SubQ, inject at any convenient time.
- TB-500: Can be injected at any time of day. Space injections 3–4 days apart during loading (e.g., Monday/Thursday or Tuesday/Friday).
- Same session: All three peptides can be administered in the same session. Use separate syringes for each injectable. No waiting period between injections.
- Injection sites: BPC-157 near the injury or abdomen; KPV in the abdomen; TB-500 works systemically from any SubQ site (abdomen is most convenient).
Cycling & Duration
This stack is typically run for 6–8 weeks, with the option to extend to 12 weeks for chronic inflammatory conditions. Periodic reassessment is important for longer cycles.
| Phase | Duration | BPC-157 | KPV | TB-500 |
|---|---|---|---|---|
| Loading | Weeks 1–4 | 250–500 mcg 1–2x/day | 200–500 mcg daily | 2–2.5 mg 2x/week |
| Maintenance | Weeks 5–8 | 250–500 mcg 1–2x/day | 200–500 mcg daily | 2–2.5 mg 1x/week |
| Extended (optional) | Weeks 9–12 | 250–500 mcg 1–2x/day | 200–500 mcg daily | 2–2.5 mg 1x/week |
| Break | 2–4 weeks off | None | None | None |
| Repeat (if needed) | 6–8 weeks | Resume full protocol | Resume full protocol | Resume with loading phase |
When to Extend to 12 Weeks
- Chronic inflammatory bowel conditions: Long-standing IBD, Crohn's-related inflammation, or chronic colitis may require extended duration for meaningful mucosal remodeling
- Autoimmune-related tissue damage: When inflammation is driven by autoimmune processes, longer suppression of the inflammatory cascade allows more complete tissue repair
- Multiple inflammatory sites: When addressing both gut inflammation and systemic joint/tissue inflammation simultaneously, a longer cycle provides adequate healing time for all affected areas
Why Take a Break?
The break period is particularly important for this stack due to KPV's immune-modulating effects. It serves to: (1) assess healing progress without peptide support, (2) confirm that improvement is structural rather than just symptomatic, (3) allow the immune system to return to baseline signaling, and (4) monitor for any signs of excessive immunosuppression from prolonged KPV use.
Safety, Side Effects & Contraindications
Common Side Effects
- Injection site redness, soreness, or minor swelling — the most common report for all injectable peptides
- Mild skin flushing — more common with KPV due to its alpha-MSH origin; typically transient
- Mild nausea — more common with BPC-157, especially oral dosing; usually resolves within days
- Transient fatigue or lethargy — occasionally reported
- Headache — may occur in the first few days of use
- Dizziness or lightheadedness — rare, typically mild and short-lived
Contraindications
- Active cancer or history of cancer: BPC-157 promotes angiogenesis and TB-500 promotes cell migration, which could theoretically support tumor growth. Avoid use with active malignancies.
- Pregnancy and breastfeeding: No safety data exists for any of these peptides during pregnancy or nursing. Avoid entirely.
- Active immunosuppressive therapy: KPV modulates immune signaling. Combining it with immunosuppressive medications may lead to excessive immune dampening. Consult your healthcare provider.
- Active infections at injection site: Do not inject through infected, inflamed, or broken skin.
- Anticoagulant therapy: BPC-157 interacts with the NO system and may affect platelet function. Consult your healthcare provider if taking blood thinners.
Stack-Specific Safety Notes
- No known negative interaction: BPC-157, KPV, and TB-500 have not been shown to interfere with each other. They operate through different mechanisms and pathways.
- KPV immunomodulation: KPV's NF-κB inhibition is beneficial for reducing inflammation but may dampen the immune response with prolonged use. Monitor for increased frequency of minor infections during extended cycles.
- Increased angiogenic load: Both BPC-157 and TB-500 promote aspects of tissue repair involving vascularization. This reinforces the theoretical concern about use with active cancers.
- Separate syringes: Use dedicated syringes for each injectable peptide to avoid any potential compatibility issues in solution.
Common Inflammation Stack Mistakes
Avoid these common errors to get the most out of your BPC-157 + KPV + TB-500 protocol:
Frequently Asked Questions
Key Takeaways
- The BPC-157 + KPV + TB-500 stack is the most comprehensive anti-inflammation peptide combination — addressing inflammation at molecular (KPV), local (BPC-157), and systemic (TB-500) levels
- BPC-157 dose: 250–500 mcg SubQ or oral 1–2x daily for localized tissue repair and gut mucosal healing
- KPV dose: 200–500 mcg SubQ or oral daily for NF-κB inhibition and molecular anti-inflammation
- TB-500 dose: 2–2.5 mg SubQ twice weekly (loading) then once weekly (maintenance) for systemic healing and cell migration
- Use oral BPC-157 and KPV for gut-focused protocols — direct mucosal contact on an empty stomach
- Typical cycle: 6–8 weeks, extendable to 12 weeks for chronic inflammatory conditions
- Monitor for immunosuppression with prolonged KPV use — take breaks between cycles
- Use separate syringes for each injectable peptide — do not mix in the same syringe
- Refrigerate reconstituted vials at 2–8°C and use within 28–30 days
- None of these peptides are FDA-approved for human use. All are classified as research peptides. Consult a healthcare provider before use.
This article is for educational and informational purposes only. See our Disclaimer.
References
- Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2018;24(18):1990-2001.
- Brzoska T, et al. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo.” Endocr Rev. 2008;29(5):581-602.
- Kannengiesser K, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis. 2008;14(3):324-331.
- Goldstein AL, et al. “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med. 2005;11(9):421-429.
- Luger TA, et al. “New insights into the functions of alpha-MSH and related peptides in the immune system.” Ann N Y Acad Sci. 2003;994:133-140.
- Seiwerth S, et al. “BPC 157's effect on healing.” J Physiol Paris. 2014;108(2-3):51-59.
- Malinda KM, et al. “Thymosin beta4 accelerates wound healing.” J Invest Dermatol. 1999;113(3):364-368.
- Getting SJ, et al. “Molecular determinants of the anti-inflammatory actions of the melanocortin peptides.” Pharmacol Ther. 2006;111(1):1-15.
- Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Curr Neuropharmacol. 2016;14(8):857-865.
Next Steps
Continue your research with these resources.
BPC-157 Dosage Guide
Complete individual dosing protocols, reconstitution, and injection guide for BPC-157.
Read GuideKPV Dosage Guide
Complete individual dosing protocols, anti-inflammatory mechanisms, and safety for KPV.
Read GuideTB-500 Dosage Guide
Complete individual dosing protocols, loading/maintenance phases, and safety for TB-500.
Read GuideDosage Calculator
Calculate exact doses for all three peptides based on vial size and reconstitution volume.
Open Calculator